The Glutathione/Metallothionein System Challenges the Design of Efficient O2‐Activating Copper Complexes

• Published in: Angewandte Chemie International Edition 2020-05, Vol.59 (20), p.7830-7835
• Main Authors: Santoro, Alice, Calvo, Jenifer S., Peris‐Díaz, Manuel David, Krężel, Artur, Meloni, Gabriele, Faller, Peter
• Format: Article
• Language: English
• Subjects: Antineoplastic drugs; Antitumor agents; Ascorbic acid; bioinorganic chemistry; Biomolecules; Catalytic activity; Coordination compounds; Copper; Copper compounds; copper-based drugs; Cytosol; Deactivation; Drugs; Glutathione; Inactivation; Metallothionein; Metallothioneins; Oxidation; redox activity; Redox properties
• ISSN: 1433-7851; 1521-3773
• DOI: 10.1002/anie.201916316

Copper complexes are of medicinal and biological interest, including as anticancer drugs designed to cleave intracellular biomolecules by O2 activation. To exhibit such activity, the copper complex must be redox active and resistant to dissociation. Metallothioneins (MTs) and glutathione (GSH) are abundant in the cytosol and nucleus. Because they are thiol‐rich reducing molecules with high CuI affinity, they are potential competitors for a copper ion bound in a copper drug. Herein, we report the investigation of a panel of CuI/CuII complexes often used as drugs, with diverse coordination chemistries and redox potentials. We evaluated their catalytic activity in ascorbate oxidation based on redox cycling between CuI and CuII, as well as their resistance to dissociation or inactivation under cytosolically relevant concentrations of GSH and MT. O2‐activating CuI/CuII complexes for cytosolic/nuclear targets are generally not stable against the GSH/MT system, which creates a challenge for their future design. Copper complexes are of medicinal and biological interest, including as anticancer drugs. O2‐activating CuI/CuII complexes for cytosolic/nuclear targets are generally not stable against glutathione and metallothioneins, which are abundant in the nucleus and cytosol. This should be considered when designing CuI/CuII complexes for biological and medicinal applications.